Important note: Information in this article was accurate in May 2009. The state of the art may have changed since the publication date.
HAART coverage and unmet need in South Africa
HIV Treat Bull - 2009 May-Jun;10(5/6): 26
Nathan Geffen, TAC
In an oral presentation, Leigh Johnson of the Centre for Actuarial Research at the University of Cape Town presented an analysis of South Africa’s HAART requirements.[1] Johnson is one of the developers of the Actuarial Society of South Africa’s AIDS models, including ASSA2003.[2]
Albeit that HAART has been available at a few public sector research and pilot sites for about a decade, the implementation of treatment in the public sector began in 2004. The number of people on treatment in both the private and public sector has risen from about 50,000 at the start of the programme in mid-2004 to about 550,000 in mid-2008.[3]
This is based on Department of Health statistics as well as Johnson’s research of private sector and NGO treatment numbers. The Department of Health data is subject to limitations. The most glaring is that five of the country’s nine provinces (Eastern Cape, Gauteng, Kwazulu-Natal, Limpopo and North West) only track the number of people who initiated treatment, not the number currently on treatment. Patients lost to follow up and deaths are therefore included in its count. To correct this, Johnson calculated a rate of retention in these provinces based on data from the Western Cape. He also checked the quality of his adjusted estimates against sales data from the pharmaceutical company supplying the bulk of the state tender.
Johnson has calculated that in mid-2004, the public sector treated less than 20% of HAART patients (the remainder were treated by the private sector and NGOs). This had increased to nearly 80% by mid-2008. He also calculated unmet need.
Using the Department’s criteria, the province with the lowest coverage is the Free State (26%). The Western Cape, at 72% has the best coverage.
To determine future need, Johnson ran various scenarios through the ASSA2003 model. He used the Department of Health’s estimates of the number of people on HAART, the District Health Barometer’s data on PMTCT and results from the Western Cape’s programme to calculate HAART effectiveness.
If the target of placing 80% of newly eligible patients on HAART is met by 2010 (80% is the target of the state’s National Strategic Plan) and current HIV incidence trends continue, then by 2011 (the end of the target period for the plan), just under 1.5 million people will be on treatment. More than 2 million people will be on treatment in 2014 and more than 3 million in 2020.
If instead, HIV incidence is halved (also a target of the state’s plan), then the consequences of this become more apparent the further into the future the estimates are projected. By 2020, half-a-million fewer people will be on treatment in this scenario.
Johnson demonstrated the substantial benefits of the HAART rollout. It conferred 24% fewer AIDS deaths in 2008, than if the programme had not been rolled out. This benefit is becoming more pronounced with time resulting in approximately 200,000 fewer deaths per year for the next decade. In 2008, there were 8% fewer maternal orphans under the age of 18 due to HAART. This becomes even more beneficial over the next 15 years, with nearly a million fewer orphans by the middle of the next decade.
Comment
Despite the actions of the Mbeki regime, particularly former Health Minister Tshabalala-Msimang, South Africa has rapidly scaled up its HAART rollout. This has been achieved because of the efforts of health workers, researchers activists and some civil servants. Nevertheless, as Johnson has demonstrated, the unmet need is substantial and growing. It will be challenging to meet the prevention and treatment targets of the National Strategic Plan.
Johnson’s painstaking analysis of the number of people on HAART as of mid-2008 across all sectors must be considered the definitive estimate of coverage for South Africa. Yet the excellent work of the Centre for Actuarial Research continues to be limited by the quality of the data from the Department of Health on numbers of patients initiated, lost-to-follow-up, currently active and died on the PMTCT and HAART programmes. The Department must prioritise improving the monitoring and evaluation of the HAART and PMTCT programmes.
References
Johnson L. How big is the need for antiretroviral treatment? 4th South African AIDS Conference, Durban, 31 March - 3 April 2009.
Department of Health. National Strategic Plan for HIV and AIDS Statistics. October 2008.
2009-05-10
IB2009-05-26
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.